AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05080322
Drug: Fluticasone Nasal 50 Mcg/Inh Nasal Spray
RxNorm normalized name: fluticasone nasal 50 mcg/inh nasal spray
DrugBank: Fluticasone (DB13867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: on-demand or maintenance
Trial: NCT04946864
Drug: APG-2575
RxNorm normalized name: APGA
DrugBank: Aminopterin (DB08878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APG2575 monotherapy
Trial: NCT04946864
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: combination APG2575+pablociclib
Trial: NCT06561763
Drug: Nimotuzumab,Toripalimab，Cisplatin, Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cisplatin 80 mg/m2， Intravenous drip administration, d1; Gemcitabine, 1000mg/m2,Intravenous ，D1,D8； Triprolizumab injection 240mg, intravenous ； Nivolumab 400mg, intravenous； Q3W 1 cycle, 3 cycles
Trial: NCT05020600
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line fibromyalgia treatment
Trial: NCT05020600
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: First-line fibromyalgia treatment
Trial: NCT05020600
Drug: Amitriptyline
RxNorm normalized name: Amitriptyline
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line fibromyalgia treatment
Trial: NCT04801589
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For patients in the dexmedetomidine group, dose will range from 0.2-2.0 mcg/kg/hr. For example, a 10 kg patient on an infusion of 1 mcg/kg/hr of dexmedetomidine would receive 10 mcg of study drug per hour. This dose range have been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the mini-MENDS study steering committee.
Trial: NCT04801589
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For patients in the midazolam group, dose will range from 0.025-0.25 mg/kg/hr. For example, a 10 kg patient on an infusion of 0.15 mg/kg/hr of midazolam would receive 1.5 mg of midazolam per hour. This dose range have been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the mini-MENDS study steering committee.
Trial: NCT06120803
Drug: Esomeprazole 40 mg
RxNorm normalized name: esomeprazole 40 MG
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enrolled patients will receive 40 mg of esomeprazole (two pills of 20 mg strength of esomeprazole) once daily before breakfast for the entire duration of TRT (including the weekends and any interim gap period) and for two weeks after completion of thoracic radiation therapy.
Trial: NCT05284760
Drug: Soticlestat
RxNorm normalized name: Soticlestat
DrugBank: Soticlestat (DB16987)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soticlestat T4 tablets.
Trial: NCT05284760
Drug: Soticlestat
RxNorm normalized name: Soticlestat
DrugBank: Soticlestat (DB16987)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soticlestat T3 mini-tablets.
Trial: NCT05284760
Drug: Soticlestat
RxNorm normalized name: Soticlestat
DrugBank: Soticlestat (DB16987)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soticlestat commercial tablets.
Trial: NCT06212245
Drug: Inebilizumab
RxNorm normalized name: INEBILIZUMAB
DrugBank: Inebilizumab (DB12530)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive IV inebilizumab 300 mg
Trial: NCT05156827
Drug: TB006
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TB006 diluted in normal saline, administered through IV infusion over an hour
Trial: NCT04510584
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab is a humanized immunoglobulin (IgG1) monoclonal antibody that targets programmed death-ligand 1 (PD-L1) on tumor-infiltrating immune cells (ICs) or tumor cells (TCs) and prevents interaction with the programmed death-1 (PD-1) receptor and B7.1 (CD80), both of which function as inhibitory receptors expressed on T cells and other immune cells.
Trial: NCT04510584
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab is a recombinant humanized IgG1 monoclonal antibody that binds VEGF, a secreted factor that stimulates angiogenesis. Bevacizumab prevents the interaction of VEGF with its receptors and neutralizes the biological activity of VEGF.
Trial: NCT05347459
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: usual and customary doses for type 2 diabetes management
Trial: NCT05347459
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: usual and customary doses for type 2 diabetes management
Trial: NCT05347459
Drug: Canagliflozin
RxNorm normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: usual and customary doses for type 2 diabetes management
Trial: NCT05347459
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: usual and customary doses for type 2 diabetes management
Trial: NCT05060588
Drug: Sacubitril/Valsartan 49/51mg/Tab
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: patients who meet the inclusion criteria are randomized to receive Sacubitril/Valsartan 24/26 mg once every 12 hours for 6 months
Trial: NCT05060588
Drug: Valsartan 80mg/Tab
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients who meet the inclusion criteria are randomized to receive valsartan one tablet every 24 hours for 6 months.
Trial: NCT04714541
Drug: Ketamine Hcl 50Mg/Ml Inj
RxNorm normalized name: KETAMINE HCL 50MG/ML INJ
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Racemic Ketamine Will Be Infused At A Starting Dose of 0.75 mg/kg Over A Period of 45 Minutes. The Dose Will be Titrated, Based on Clinical Signs With Changes of 0.3mg/kg Up to Maximum of 0.95 mg/kg, and Lowest Dose of 0.3 mg/kg
Trial: NCT05347459
Drug: Saxagliptin
RxNorm normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: usual and customary doses for type 2 diabetes management
Trial: NCT05347459
Drug: Linagliptin
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: usual and customary doses for type 2 diabetes management
Trial: NCT05347459
Drug: Vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: usual and customary doses for type 2 diabetes management
Trial: NCT06008990
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregnant mother must be taking Buprenorphine
Trial: NCT05507580
Drug: Upadacitinib
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral tablet
Trial: NCT04925609
Drug: Brigatinib
RxNorm normalized name: Brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Brigatinib is a second generation novel, orally administered, tyrosine kinase inhibitor (TKI) that potently inhibits activated variants of ALK and to a lesser extent ROS1.
Trial: NCT05412576
Drug: Lidocaine Hydrochloride 2% Injection Solution
RxNorm normalized name: Lidocaine Hydrochloride 2% Injection Solution
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injectable
Trial: NCT04807348
Drug: Chiglitazar 32mg
RxNorm normalized name: Chiglitazar
DrugBank: Chiglitazar (DB19023)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrated once daily
Trial: NCT04807348
Drug: Chiglitazar 48mg
RxNorm normalized name: Chiglitazar
DrugBank: Chiglitazar (DB19023)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrated once daily
Trial: NCT04807348
Drug: Metformin Hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: most tolerable dose
Trial: NCT04705519
Drug: Nab-paclitaxel Combined With Bevacizumab
RxNorm normalized name: Paclitaxel
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel 150mg/m2 ，iv drip, d1, Bevacizumab 5mg/kg, iv drip, d1, q2w.
Trial: NCT05610319
Drug: Faricimab
RxNorm normalized name: Faricimab
DrugBank: Faricimab (DB15303)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Faricimab will be administered via intravitreal injection.
Trial: NCT06565611
Drug: bremelanotide
RxNorm normalized name: Bremelanotide
DrugBank: Bremelanotide (DB11653)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bremelanotide (BMT) sterile aqueous solution for subcutaneous injection, provided as autoinjectors containing 0.3 mL volume
Trial: NCT06565611
Drug: tirzepatide
RxNorm normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tirzepatide (GLP-1/GIP) will be provided in its commercial form for SC injection.
Trial: NCT06564207
Drug: Fostamatinib
RxNorm normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fostamatinib 150mg to be given twice daily for 14 days
Trial: NCT05981573
Drug: Measurement of Methadone in the Interstitial Fluid before and after prescribed dose taken in vivo
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Measurement of Methadone and its metabolites in ISF with LC-MS and RMM
Trial: NCT05619627
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive oral dexmedetomidine as the sole sedative agent for undergoing MRI
Trial: NCT04778410
Drug: Magrolimab
RxNorm normalized name: Magrolimab
DrugBank: Magrolimab (DB16225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT04778410
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered either subcutaneously or IV, 75 mg/milligram per square (m\^2) on Days 1 to 7 or Days 1 to 5, 8 and 9 during every cycle
Trial: NCT04778410
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally at a dose of 100 mg on Day 1, 200 mg on Day 2, 400 mg on Days 3-28 during Cycle 1, followed by 400 mg on Days 1-28 during every cycle
Trial: NCT04778410
Drug: Mitoxantrone
RxNorm normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravenously, 8 mg/m\^2 on Days 1-5 during Cycle 1 to Cycle 3
Trial: NCT05401786
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-CTLA-4
Trial: NCT04778410
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously, 100 mg/m\^2 on Days 1-5 during Cycle 1 to Cycle 3
Trial: NCT05401786
Drug: Cemiplimab
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: PD-1 inhibition
Trial: NCT05113953
Drug: Centanafadine
RxNorm normalized name: Centanafadine
DrugBank: Centanafadine (DB14841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release oral tablets
Trial: NCT05627115
Drug: Tislelizumab, AVD, Radiotherapy
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GROUP A: Early stage disease without adverse features in CMR: 2 further cycles tislelizumab then radiotherapy then 200mg IV tislelizumab once every 3 weeks until a maximum of 2 years total treatment. PET-CT (PET2) 12 weeks after radiotherapy.~GROUP B: Early stage disease with adverse features in CMR: 2 cycles of AVD plus tislelizumab then radiotherapy. PET-CT (PET2) 12 weeks after the completion of radiotherapy.~GROUP C: All early stage disease not in CMR: 4 cycles of AVD plus tislelizumab then PET-CT and radiotherapy. PET-CT 12 (PET2) weeks after radiotherapy.~GROUP D: Advanced stage disease in CMR: 4 cycles of AVD plus tislelizumab then radiotherapy at investigator's discretion. PET-CT (PET2) 12 weeks after radiotherapy.~GROUP E: Advanced stage disease not in CMR: 6 cycles of AVD plus tislelizumab then PET-CT then radiotherapy at investigator's discretion. PET-CT (PET2) 12 weeks after radiotherapy.
Trial: NCT04778410
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously, 1000 mg/m\^2 on Days 1-5 during Cycle 1 to Cycle 3
Trial: NCT04778410
Drug: CC-486
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally, 300 mg on Days 1-14 during each cycle
Trial: NCT05385861
Drug: nanoliposomal irinotecan plus carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose in phase 1 cohort:~Dose level 1= nanoliposomal irinotecan 100 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk~Dose level 0= nanoliposomal irinotecan 80 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk~Dose level -1= nanoliposomal irinotecan 60 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk~Carboplatin dose (mg) is calculated by the Calvert formula: AUC x (eGFR + 25). Cockcroft-Gault equation: eGFR (calculated Ccr)= \[(140-age) x weight x 0.85 (if female)\] / (72 x serum Cr). The maximum eGFR for dose calculation is 125 ml/min.~In Phase 2 Cohort Patients will be treated until disease progression, unacceptable toxicity or other condition meeting the treatment discontinuation criteria.
Trial: NCT04974684
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients implanted with HeartMate 3 will be randomized in 2:1 ratio in interventional and control group. Patients in interventional group will be switched to therapy with apixaban instead of warfarin.
Trial: NCT06558695
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane was managed for maintenance of the general anestesia during spinal surgeries
Trial: NCT06558695
Drug: TIVA
RxNorm normalized name: Ultiva
DrugBank: Platelet Activating Factor (DB02261)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIVA was managed for maintenance of the general anesthesia during spinal surgeries
Trial: NCT05813847
Drug: local anaesthetic injection
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local infiltration of study drug
Trial: NCT06504940
Drug: Orelabrutinib combined with bendamustine and rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: they will receive three cycles of Orelabrutinib combined with bendamustine and rituximab (BR: bendamustine 70mg/m\^2 on days 1-2; rituximab 375mg/m\^2 on day 0). Patients achieving PR or better will enter the Orelabrutinib monotherapy maintenance phase (up to 21 cycles, each cycle 28 days).
Trial: NCT06504940
Drug: Orelabrutinib combined with obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Rutin (DB01698)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: they will receive six cycles of Orelabrutinib combined with obinutuzumab (G 1000mg iv on days 1, 8, 15 of cycle 1, and day 1 of cycles 2-6; Orelabrutinib 150mg once daily). Patients achieving PR or better will enter the Orelabrutinib monotherapy maintenance phase (up to 18 cycles, each cycle 28 days ).
Trial: NCT01996501
Drug: Olanzapine Orally Disintegrating 5mg Tablets
RxNorm normalized name: olanzapine Disintegrating Oral Product
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05672342
Drug: Cannabidiol
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT05672342
Drug: Delta-8-Tetrahydrocannabinol
RxNorm normalized name: .DELTA.8-TETRAHYDROCANNABINOL
DrugBank: Cannabinol (DB14737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06425003
Drug: [14C] ABBV-CLS-7262
DrugBank: ABBV-CLS-7262 (DB18407)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Solution
Trial: NCT04385173
Drug: B7-H3 CAR-T
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The B7-H3 CAR-T will be administrated via intratumoral or Intracerebroventricular injection through an Ommaya catheter in between Temozolomide cycles. Temozolomide will be stopped during the infusion of B7-H3 CAR-T
Trial: NCT04385173
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide will be given to patients orally every 5 days with 23 days interval. The initial dose is 150 mg/m2 on the first day and 200 mg/m2 for the rest if no toxicity is seen. If 200 mg/m2 is toxic, the drug will return to 150 mg/m2 or will be stopped.
Trial: NCT05118256
Drug: Pirfenidone Oral Tablet
RxNorm normalized name: pirfenidone Oral Tablet
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be treated with pirfenidone (oral tablets) during 6 months
Trial: NCT05738850
Drug: ABBV-932
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsule
Trial: NCT05438316
Drug: Ramipril tablet 10 mg
RxNorm normalized name: ramipril Oral Tablet
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramipril is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 10 mg of ramipril.
Trial: NCT06407310
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: I.V Pembrolizumab (keytruda) 200 mg every 3 weeks for 6 cycles
Trial: NCT06407310
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: I.V Carboplatin at AUC 1.5 weekly for a total of 12 weeks.
Trial: NCT06407310
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: I.V Paclitaxel at 80 mg/m2 weekly for a total of 12 weeks.
Trial: NCT06366243
Drug: Emraclidine
RxNorm normalized name: Emraclidine
DrugBank: Emraclidine (DB18706)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT06366243
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral delayed-release capsule
Trial: NCT05735145
Drug: paclitaxel combined with platinum
RxNorm normalized name: platinum
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adjuvant chemotherapy with paclitaxel combined with platinum
Trial: NCT05270343
Drug: Cholecalciferol (Vit D3) 400Unit Cap
RxNorm normalized name: CHOLECALCIFEROL (VIT D3) 400UNIT CAP
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will take Vit D3 (400Unit Cap) with breakfast for 12 consecutive months, and the initial load will be 140IU/kg qd until the serum 25(OH)D3 is maintained at the upper limit of normal ( 50-80ng/ml\[125-200nmol/L\], ≤100ng/ml\[≤250nmol/L\]), then maintained at 70IU/kg qd, combined with intensive insulin therapy
Trial: NCT05253508
Drug: Lidocaine 2% Injectable Solution
RxNorm normalized name: lidocaine 2% injectable solution
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A digital nerve block by injections to the base of the finger
Trial: NCT05651256
Drug: Botulinum toxin type A injection
RxNorm normalized name: botulinum toxin type A Injection
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: The solution for injection was prepared immediately before the intervention, by dissolving the vials of BTX, kept refrigerated at 5ºC, in 1 ml of sterile saline solution at room temperature. Eight injection sites were marked, three located in the masseter muscle, two in the lateral pterygoid muscle, one in the temporomandibular joint (TMJ) and two in the temporalis muscle. A 1 cc marked insulin syringe was used for intramuscular injection of the prepared solution, according to the locations and amounts proposed by Kim et al. and Ho et al. with a total dose of 100 U in each patient.distributed at the different injection sites.
Trial: NCT06548204
Drug: Fexofenadine Hydrochloride 60mg bid
RxNorm normalized name: fexofenadine hydrochloride 60 MG
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine hydrochloride 60mg bid treatment for 6 months.
Trial: NCT06548204
Drug: Fexofenadine Hydrochloride 120mg bid
RxNorm normalized name: fexofenadine hydrochloride 120 MG
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine hydrochloride 120mg bid treatment for 6 months.
Trial: NCT03678480
Drug: Ursodeoxycholic Acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA capsules, 125mg
Trial: NCT04747171
Drug: intrathecal Magnesium
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intrathecal adjuvants to bupivacaine
Trial: NCT04747171
Drug: intrathecal dexamthasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intrathecal adjuvants to bupivacaine